261 related articles for article (PubMed ID: 29659889)
1. Anti-Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus Disease.
Brown JF; Dye JM; Tozay S; Jeh-Mulbah G; Wohl DA; Fischer WA; Cunningham CK; Rowe K; Zacharias P; van Hasselt J; Norwood DA; Thielman NM; Zak SE; Hoover DL
J Infect Dis; 2018 Jul; 218(4):555-562. PubMed ID: 29659889
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States.
Dean CL; Hooper JW; Dye JM; Zak SE; Koepsell SA; Corash L; Benjamin RJ; Kwilas S; Bonds S; Winkler AM; Kraft CS
Transfusion; 2020 May; 60(5):1024-1031. PubMed ID: 32129478
[TBL] [Abstract][Full Text] [Related]
3. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus.
Luczkowiak J; Arribas JR; Gómez S; Jiménez-Yuste V; de la Calle F; Viejo A; Delgado R
Virus Res; 2016 Feb; 213():224-229. PubMed ID: 26739425
[TBL] [Abstract][Full Text] [Related]
4. Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection.
Rimoin AW; Lu K; Bramble MS; Steffen I; Doshi RH; Hoff NA; Mukadi P; Nicholson BP; Alfonso VH; Olinger G; Sinai C; Yamamoto LK; Ramirez CM; Okitolonda Wemakoy E; Kebela Illunga B; Pettitt J; Logue J; Bennett RS; Jahrling P; Heymann DL; Piot P; Muyembe-Tamfum JJ; Hensley LE; Simmons G
J Infect Dis; 2018 Jan; 217(2):223-231. PubMed ID: 29253164
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of Ebola Virus Disease Survivor Blood and Semen in Liberia: Serology and Reverse Transcription Polymerase Chain Reaction (RT-PCR).
Kofman A; Linderman S; Su K; Purpura LJ; Ervin E; Brown S; Morales-Betoulle M; Graziano J; Cannon DL; Klena JD; Desamu-Thorpe R; Fankhauser J; Orone R; Moses S; Glaybo U; Massaquoi M; Nyenswah T; Nichol ST; Kollie J; Kiawu A; Freeman E; Giah G; Tony H; Faikai M; Jawara M; Kamara K; Kamara S; Flowers B; Mohammed K; Chiriboga D; Williams DE; Hinrichs SH; Ahmed R; Vonhm B; Rollin PE; Choi MJ
Clin Infect Dis; 2021 Dec; 73(11):e3641-e3646. PubMed ID: 32894277
[TBL] [Abstract][Full Text] [Related]
6. Serological Investigation of Laboratory-Confirmed and Suspected Ebola Virus Disease Patients During the Late Phase of the Ebola Outbreak in Sierra Leone.
Liu Y; Sun Y; Wu W; Li A; Yang X; Zhang S; Li C; Su Q; Cai S; Sun D; Hu H; Zhang Z; Yang X; Kamara I; Koroma S; Bangura G; Tia A; Kamara A; Lebby M; Kargbo B; Li J; Wang S; Dong X; Shu Y; Xu W; Gao GF; Wu G; Li D; Liu WJ; Liang M
Virol Sin; 2018 Aug; 33(4):323-334. PubMed ID: 30066045
[TBL] [Abstract][Full Text] [Related]
7. Atypical Ebola Virus Disease in a Nonhuman Primate following Monoclonal Antibody Treatment Is Associated with Glycoprotein Mutations within the Fusion Loop.
Banadyga L; Zhu W; Kailasan S; Howell KA; Franaszek K; He S; Siragam V; Cheng K; Yan F; Moffat E; Cao W; Leung A; Embury-Hyatt C; Aman MJ; Qiu X
mBio; 2021 Jan; 12(1):. PubMed ID: 33436428
[TBL] [Abstract][Full Text] [Related]
8. Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans.
Vu H; Shulenin S; Grolla A; Audet J; He S; Kobinger G; Unfer RC; Warfield KL; Aman MJ; Holtsberg FW
Antiviral Res; 2016 Feb; 126():55-61. PubMed ID: 26681387
[TBL] [Abstract][Full Text] [Related]
9. Zoonotic risk factors associated with seroprevalence of Ebola virus GP antibodies in the absence of diagnosed Ebola virus disease in the Democratic Republic of Congo.
Bratcher A; Hoff NA; Doshi RH; Gadoth A; Halbrook M; Mukadi P; Musene K; Ilunga-Kebela B; Spencer D; Bramble MS; McIlwan D; Kelly JD; Mukadi D; Kingebeni PM; Ahuka S; Okitolonda-Wemakoy E; Muyembe-Tamfum JJ; Rimoin AW
PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009566. PubMed ID: 34383755
[TBL] [Abstract][Full Text] [Related]
10. Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins.
Koch T; Rottstegge M; Ruibal P; Gomez-Medina S; Nelson EV; Escudero-Pérez B; Pillny M; Ly ML; Koundouno FR; Bore JA; Magassouba N; Dahlke C; Günther S; Carroll MW; Addo MM; Muñoz-Fontela C
Viruses; 2020 Aug; 12(9):. PubMed ID: 32825479
[TBL] [Abstract][Full Text] [Related]
11. Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra Leone.
Tedder RS; Samuel D; Dicks S; Scott JT; Ijaz S; Smith CC; Adaken C; Cole C; Baker S; Edwards T; Kamara P; Kargbo O; Niazi S; Nwakanma D; d'Alessandro U; Burch G; Doughty H; Brown CS; Andrews N; Glynn JR; van Griensven J; ; Pollakis G; Paxton WA; Semple MG
Transfusion; 2018 May; 58(5):1289-1298. PubMed ID: 29572862
[TBL] [Abstract][Full Text] [Related]
12. Ebola virus-induced eye sequelae: a murine model for evaluating glycoprotein-targeting therapeutics.
Lee HN; Xu B; Lewkowicz AP; Engel K; Kelley-Baker L; McWilliams IL; Ireland DDC; Kielczewski JL; Li J; Fariss RN; Campos MM; Baum A; Kyratsous C; Pascal K; Chan CC; Caspi RR; Manangeeswaran M; Verthelyi D
EBioMedicine; 2024 Jun; 104():105170. PubMed ID: 38823088
[TBL] [Abstract][Full Text] [Related]
13. A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice.
Chen T; Li D; Song Y; Yang X; Liu Q; Jin X; Zhou D; Huang Z
Antiviral Res; 2017 Sep; 145():54-59. PubMed ID: 28733113
[TBL] [Abstract][Full Text] [Related]
14. Scalable, semi-automated fluorescence reduction neutralization assay for qualitative assessment of Ebola virus-neutralizing antibodies in human clinical samples.
Postnikova EN; Pettitt J; Van Ryn CJ; Holbrook MR; Bollinger L; Yú S; Caì Y; Liang J; Sneller MC; Jahrling PB; Hensley LE; Kuhn JH; Fallah MP; Bennett RS; Reilly C
PLoS One; 2019; 14(8):e0221407. PubMed ID: 31454374
[TBL] [Abstract][Full Text] [Related]
15. A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals.
Herrera BB; Hamel DJ; Oshun P; Akinsola R; Akanmu AS; Chang CA; Eromon P; Folarin O; Adeyemi KT; Happi CT; Lu Y; Ogunsola F; Kanki PJ
PLoS Negl Trop Dis; 2018 May; 12(5):e0006530. PubMed ID: 29795572
[TBL] [Abstract][Full Text] [Related]
16. Broad Neutralizing Activity Against Ebolaviruses Lacking the Mucin-Like Domain in Convalescent Plasma Specimens From Patients With Ebola Virus Disease.
Luczkowiak J; Lasala F; Mora-Rillo M; Arribas JR; Delgado R
J Infect Dis; 2018 Nov; 218(suppl_5):S574-S581. PubMed ID: 29939289
[TBL] [Abstract][Full Text] [Related]
17. Ebola virus antibody decay-stimulation in a high proportion of survivors.
Adaken C; Scott JT; Sharma R; Gopal R; Dicks S; Niazi S; Ijaz S; Edwards T; Smith CC; Cole CP; Kamara P; Kargbo O; Doughty HA; van Griensven J; Horby PW; Gevao SM; Sahr F; ; Dimelow RJ; Tedder RS; Semple MG; Paxton WA; Pollakis G
Nature; 2021 Feb; 590(7846):468-472. PubMed ID: 33505020
[TBL] [Abstract][Full Text] [Related]
18. High degree of correlation between Ebola virus BSL-4 neutralization assays and pseudotyped VSV BSL-2 fluorescence reduction neutralization test.
Konduru K; Shurtleff AC; Bavari S; Kaplan G
J Virol Methods; 2018 Apr; 254():1-7. PubMed ID: 29355585
[TBL] [Abstract][Full Text] [Related]
19. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.
Bornholdt ZA; Turner HL; Murin CD; Li W; Sok D; Souders CA; Piper AE; Goff A; Shamblin JD; Wollen SE; Sprague TR; Fusco ML; Pommert KB; Cavacini LA; Smith HL; Klempner M; Reimann KA; Krauland E; Gerngross TU; Wittrup KD; Saphire EO; Burton DR; Glass PJ; Ward AB; Walker LM
Science; 2016 Mar; 351(6277):1078-83. PubMed ID: 26912366
[TBL] [Abstract][Full Text] [Related]
20. Comparative Evaluation of the Diagnostic Performance of the Prototype Cepheid GeneXpert Ebola Assay.
Jansen van Vuren P; Grobbelaar A; Storm N; Conteh O; Konneh K; Kamara A; Sanne I; Paweska JT
J Clin Microbiol; 2016 Feb; 54(2):359-67. PubMed ID: 26637383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
